問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

李欣學Li, Sin-Syue
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

81Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李欣學

List

134Cases

2019-05-01 - 2021-10-31

Phase II

An Open-Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor-Naive or Have Not Recently Received Complement Inhibitor Therapy

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    REGN3918N

Participate Sites
4Sites

Recruiting4Sites

2019-10-01 - 2022-12-12

Phase III

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria

  • Test Drug

    R3918

Participate Sites
4Sites

Recruiting4Sites

2018-01-31 - 2026-02-08

Phase III

A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

  • Condition/Disease

    Acute Myeloid Leukemia, AML

  • Test Drug

    Glasdegib (PF-04449913)

Participate Sites
5Sites

Recruiting5Sites

高志平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-01-15 - 2020-01-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-01-31 - 2017-02-10

Phase I

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 in adult patients with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736.

  • Condition/Disease

    NSCLC

  • Test Drug

    MEDI4736 & Tremelimumab

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

2015-04-01 - 2022-04-22

Phase III

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma (MM)

  • Test Drug

    Pomalidomide

Participate Sites
8Sites

Terminated7Sites

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華
Taipei Veterans General Hospital

Division of Thoracic Medicine

2017-07-20 - 2025-05-20

Phase III

A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

  • Condition/Disease

    Lymphoma, Non-Hodgkin

  • Test Drug

    BAY 80-6946 (copanlisib)；phosphatidylinositol 3-kinase (PI3K) inhibitor

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2017-05-16 - 2022-07-26

Phase III

A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3

  • Condition/Disease

    Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

  • Test Drug

    BAY 80-6946 (copanlisib)；phosphatidylinositol 3-kinase (PI3K) inhibitor

Participate Sites
5Sites

Terminated5Sites

2016-02-01 - 2020-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 10 11 12 13 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB